Naslov
Smoking-related interstitiallung disease

Autori
Peroš-Golubičić, Tatjana

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, stručni

Izvornik
Zbornik povzetkov ; 4th Meeting of three Respiratory Societies / Triller, Nadja - Bled, 2015, 22-22

Skup
4th Meeting of three Respiratory Societies

Mjesto i datum
Slovenija, 22.05.2015. - 23.05.2015

Vrsta sudjelovanja
Predavanje

Vrsta recenzije
Nije recenziran

Ključne riječi
Smoking; interstitial lung disease

Sažetak
Smoking is a risk factor for the genesis of number of ILD. SR-ILD comprise of entities known to have a strong epidemiological association with smoking, like respiratory-bronchiolitis-associated interstitial lung disease(RB-ILD), desquamative interstitial pneumonia(DIP) and pulmonary Langerhans cell histiocytosis(PLCH). Smoking-related interstitial fibrosis(SRIF) is a distinct form of chronic interstitial fibrosis, denoted by thickening of alveolar septa by collagen deposition with minimal inflammation. It is important to separate SRIF which has a relatively benign course from both UIP and fibrosing NSIP. The histologic appearance of lung injury secondary to cigarette smoke is diverse and consist of smokers’ macrophages within airspaces, which may be airway centered(RB) or diffuse(DIP) in distribution, emphysema, small-airway injury with fibrosis, remodeling that results in distortion, thickening of walls of small arteries and arterioles, stellate cellular and fibrotic lesions of PLCH and alveolar wall fibrosis. SR-ILD are considered as distinct clinical entities but they share a number of clinical, radiological and pathological features, suggesting that they represent a spectrum of patterns of ILDs occurring in predisposed individuals who smoke. The patient suspected to suffer from SR-ILD should be referred to the pulmonologist. Early treatment with novel, even targeted therapies like in some LCH cases, and smoking cessation can improve clinical outcomes.

Izvorni jezik
Engleski

POVEZANOST RADA